News dalla rete ITA

25 Novembre 2021



Media reports suggest that eight months after the government imposed a hold on all major exports of Covid-19 vaccines, the Serum Institute of India (SII) is likely to start supplying Covishield this week to the Covax international vaccine facility. The company is expected to supply 25 million doses to the Covax facility led by the Gavi vaccine alliance, World Health Organization and the Coalition for Epidemic Preparedness Innovations till the end of December. India had suspended exports of Covid vaccines at the beginning of the second wave of the pandemic. Meanwhile media reports highlighted US drugmaker Pfizer’s deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world's population. India is one of the 95 countries where Pfizer will allow the sale of its Covid-19 pill, Paxlovid, at a lower cost as per an agreement that the pharmaceutical giant inked with Medicines Patent Pool, a United Nations-backed public health organisation. Under the terms of the agreement, Pfizer will not receive royalties on sales in low-income countries and will waive royalties on sales in all countries covered by the agreement while COVID-19 remains a public health emergency. Pfizer's licensing deal follows a similar arrangement by Merck & Co (MRK.N) for generic manufacturing of its COVID-19 treatment. Merck has licence agreements for it COVID-19 pill, molnupiravir, in over 100 countries. Dr Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new Covid-19 pill developed by Merck, said it was open to making the similar pill from Pfizer. (ICE NEW DELHI)

Fonte notizia: The Economic Times